Clinical trials: Moderate to Severe Glabellar Lines
Glabellar Lines
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.
- Trial name
- NCT05428930
- Testing
- CKDB-501B, Botox®50U
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- CKD Bio Corporation
Glabellar Frown Lines
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT03440671
- Testing
- Hutox Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Huons Co., Ltd.
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
The study objective was to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770029
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Xeomin in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.
- Trial name
- NCT05305768
- Testing
- IncobotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Clinical Testing of Beverly Hills
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- 21 sites in United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Glabellar Lines
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
A multicenter, double-blind, randomized, parallel design, active control, phase 3 clinical trial to evaluate the efficacy and safety of 100 units of BMI 2006 and Botox® in adult patients in need of moderate or severe glabellar…
- Trial name
- BMI2006 (NCT05531968)
- Testing
- BMI2006, BOTOX®
- Where
- 3 sites in South Korea
- Volunteers
- 278 people
- Sponsor
- BMI Korea
Moderate-severe Glabellar Lines
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
Evaluate onset time and safety of improvement effect of each group's forehead wrinkles after 2, 3, 4, 5, 14 days from administration of 20U dosage of DWP450-004 for adult patients who need more than moderate improvement of…
- Trial name
- NCT02568150
- Testing
- Single group, open-label
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Lines
A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety, immunogenicity and efficacy of JHM03 for the treatment of moderate to severe glabellar lines in male…
- Trial name
- NCT06199336
- Testing
- JHM03, BOTOX®
- Where
- China
- Volunteers
- 190 people
- Sponsor
- JHM BioPharma (Tonghua) Co. , Ltd.
Moderate to Severe Glabellar Lines
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male…
- Trial name
- NCT05743634
- Testing
- YY001, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 140 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Frown Lines
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
- Trial name
- NCT05217355
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Medytox Korea
Glabellar Frown Lines
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06585696
- Testing
- CU-20101 treatment for Moderate to Severe Glabellar Striae, BOTOX®
- Where
- China
- Volunteers
- 554 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Glabellar Lines
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT06205797
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Lines
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
To evaluate the efficacy and safety of HG102 for moderate to severe Glabellar Lines, non-inferiority compared to Botox® was confirmed and safety was evaluated.
- Trial name
- NCT05801146
- Testing
- Botulinum Toxin Type A Injection [HG102], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 272 people
- Sponsor
- Hugel
Glabellar Frown Lines
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label…
- Trial name
- NCT04143815
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Glabellar Lines
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Glabellar lines.
- Trial name
- NCT05292638
- Testing
- CKDB-501A, Botox®
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- CKD Bio Corporation
Glabellar Lines
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06308198
- Testing
- AGN-151586
- Where
- 12 sites in China, Japan and 1 more
- Volunteers
- 161 people
- Sponsor
- AbbVie
Glabellar Lines
Phase 2 of HU-045 in Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT05298449
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Huons Co., Ltd.
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA I (NCT04594213)
- Testing
- NT 201
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.
- Trial name
- NCT05321979
- Testing
- MBA-P01
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Medytox Korea